Evidence map›Paper›PMID 42267312›Full record

ArticleInternational journal of nanomedicine2026

PLGA-PEG Nano-Adjuvant-Delivered ClfA Vaccine Elicits IL-17A-Mediated Neutrophil Activation to Confer Complete Protection Against Methicillin-Resistant

Zhuoyue Shi, Zhuo Wan, Guodong Tan, Jiayue Xi, Minxuan Cui, Yufei Hou, Zhengjun Ma, Nan Sun, Yupu Zhu, Muqiong Li and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of nanomedicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Zhuoyue Shi *Department of Pharmaceutical Chemistry and Analysis (Shaanxi Key Laboratory of Chiral Drug and Vaccine Adjuvants), School of Pharmacy, Air Force Medical University, Xi'an, Shaanxi, People's Republic of China.
Zhuo Wan *Department of Pharmaceutical Chemistry and Analysis (Shaanxi Key Laboratory of Chiral Drug and Vaccine Adjuvants), School of Pharmacy, Air Force Medical University, Xi'an, Shaanxi, People's Republic of China.
Guodong Tan *Air Force Medical Center, Fourth Military Medical University, Beijing, People's Republic of China.
Jiayue XiDepartment of Pharmaceutical Chemistry and Analysis (Shaanxi Key Laboratory of Chiral Drug and Vaccine Adjuvants), School of Pharmacy, Air Force Medical University, Xi'an, Shaanxi, People's Republic of China.
Minxuan CuiDepartment of Pharmaceutical Chemistry and Analysis (Shaanxi Key Laboratory of Chiral Drug and Vaccine Adjuvants), School of Pharmacy, Air Force Medical University, Xi'an, Shaanxi, People's Republic of China.
Yufei HouDepartment of Pharmaceutical Chemistry and Analysis (Shaanxi Key Laboratory of Chiral Drug and Vaccine Adjuvants), School of Pharmacy, Air Force Medical University, Xi'an, Shaanxi, People's Republic of China.
Zhengjun MaDepartment of Pharmaceutical Chemistry and Analysis (Shaanxi Key Laboratory of Chiral Drug and Vaccine Adjuvants), School of Pharmacy, Air Force Medical University, Xi'an, Shaanxi, People's Republic of China.ORCID 0009-0002-5099-5934
Nan SunDepartment of Pharmaceutical Chemistry and Analysis (Shaanxi Key Laboratory of Chiral Drug and Vaccine Adjuvants), School of Pharmacy, Air Force Medical University, Xi'an, Shaanxi, People's Republic of China.
Yupu ZhuDepartment of Occupational & Environmental Health and the Ministry of Education Key Laboratory of Hazard Assessment and Control in Special Operational Environment, School of Public Health, Air Force Medical University, Xi'an, Shaanxi, People's Republic of China.
Muqiong LiDepartment of Pharmaceutical Chemistry and Analysis (Shaanxi Key Laboratory of Chiral Drug and Vaccine Adjuvants), School of Pharmacy, Air Force Medical University, Xi'an, Shaanxi, People's Republic of China.
Dong WangDepartment of Pharmaceutical Chemistry and Analysis (Shaanxi Key Laboratory of Chiral Drug and Vaccine Adjuvants), School of Pharmacy, Air Force Medical University, Xi'an, Shaanxi, People's Republic of China.
Xin HeDepartment of Pharmaceutical Chemistry and Analysis (Shaanxi Key Laboratory of Chiral Drug and Vaccine Adjuvants), School of Pharmacy, Air Force Medical University, Xi'an, Shaanxi, People's Republic of China.
Qian YangDepartment of Chinese Materia Medical and Natural Medicines, School of Pharmacy, Air Force Medical University, Xi'an, Shaanxi, People's Republic of China.
Chaojun SongSchool of Life Science and Technology, Northwestern Polytechnical University, Xi'an, Shaanxi, People's Republic of China.
Li FanDepartment of Pharmaceutical Chemistry and Analysis (Shaanxi Key Laboratory of Chiral Drug and Vaccine Adjuvants), School of Pharmacy, Air Force Medical University, Xi'an, Shaanxi, People's Republic of China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Purpose: Methicillin-resistant Methods: We constructed a nano-vaccine using PLGA Results: Compared to the aluminum-adjuvanted vaccine, the 25%NPs-rClfA nano-vaccine elicited lower specific antibody titers but generated antibodies with superior neutralizing activity. It significantly enhanced the secretion of IFN-γ and IL-17A, with IL-17A sustaining elevated levels over an extended period. Crucially, the nano-vaccine conferred 100% protection against death following lethal Conclusion: This study demonstrates that the PLGA-PEG nanoparticle-based rClfA nano-vaccine can effectively redirect immune responses toward protective Th1/Th17 immunity and robustly protect against lethal

Indexed as

Interleukin-17Methicillin-Resistant Staphylococcus aureusNeutrophil ActivationPolyethylene GlycolsStaphylococcal InfectionsStaphylococcal VaccinesAdjuvants, ImmunologicAdjuvants, VaccineAnimalsAntibodies, BacterialFemaleMiceMice, Inbred BALB CNanoparticlesNanovaccinesPolylactic Acid-Polyglycolic Acid CopolymerAdjuvants, ImmunologicAdjuvants, VaccineAntibodies, BacterialInterleukin-17NanovaccinesPolyethylene GlycolsPolylactic Acid-Polyglycolic Acid CopolymerProtein Subunit VaccinesStaphylococcal Vaccinesinterleukin-17Anano-adjuvantneutrophilreactive oxygen speciesStaphylococcus aureusvaccine

Identifiers

PMID42267312
PMCPMC13242998

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.